Contemporary Management of Pineoblastoma

Matthew C. Tate; Martin J. Rutkowski; Andrew T. Parsa

doi:10.1016/j.nec.2011.05.001

Contemporary Management of Pineoblastoma

Matthew C. Tate, Martin J. Rutkowski, Andrew T. Parsa^*

^*Corresponding author for this work

Neurological Surgery

Research output: Contribution to journal › Review article › peer-review

22 Scopus citations

Abstract

Pineoblastomas (PBs) represent the most aggressive of the pineal parenchymal tumors. Routine treatment consists of operative management of obstructive hydrocephalus and cerebrospinal fluid studies followed by maximal resection and adjuvant chemotherapy/radiotherapy, resulting in a median survival of 20 months. Important prognostic factors for survival of patients with PB include extent of resection, age at presentation, disseminated disease, and craniospinal radiotherapy. Novel strategies being evaluated for the treatment of PB include high-dose chemotherapy with autologous stem cell therapy, stereotactic radiosurgery, and histone deacetylase inhibitors.

Original language	English (US)
Pages (from-to)	409-412
Number of pages	4
Journal	Neurosurgery Clinics of North America
Volume	22
Issue number	3
DOIs	https://doi.org/10.1016/j.nec.2011.05.001
State	Published - Jul 1 2011

Keywords

Pineoblastoma
Survival
Treatment

ASJC Scopus subject areas

Clinical Neurology
Surgery

Access to Document

10.1016/j.nec.2011.05.001

Cite this

@article{160aa24e2ecf4ffbbb32ad4334fc99b0,

title = "Contemporary Management of Pineoblastoma",

abstract = "Pineoblastomas (PBs) represent the most aggressive of the pineal parenchymal tumors. Routine treatment consists of operative management of obstructive hydrocephalus and cerebrospinal fluid studies followed by maximal resection and adjuvant chemotherapy/radiotherapy, resulting in a median survival of 20 months. Important prognostic factors for survival of patients with PB include extent of resection, age at presentation, disseminated disease, and craniospinal radiotherapy. Novel strategies being evaluated for the treatment of PB include high-dose chemotherapy with autologous stem cell therapy, stereotactic radiosurgery, and histone deacetylase inhibitors.",

keywords = "Pineoblastoma, Survival, Treatment",

author = "Tate, {Matthew C.} and Rutkowski, {Martin J.} and Parsa, {Andrew T.}",

year = "2011",

month = jul,

day = "1",

doi = "10.1016/j.nec.2011.05.001",

language = "English (US)",

volume = "22",

pages = "409--412",

journal = "Neurosurgery Clinics of North America",

issn = "1042-3680",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Contemporary Management of Pineoblastoma

AU - Tate, Matthew C.

AU - Rutkowski, Martin J.

AU - Parsa, Andrew T.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Pineoblastomas (PBs) represent the most aggressive of the pineal parenchymal tumors. Routine treatment consists of operative management of obstructive hydrocephalus and cerebrospinal fluid studies followed by maximal resection and adjuvant chemotherapy/radiotherapy, resulting in a median survival of 20 months. Important prognostic factors for survival of patients with PB include extent of resection, age at presentation, disseminated disease, and craniospinal radiotherapy. Novel strategies being evaluated for the treatment of PB include high-dose chemotherapy with autologous stem cell therapy, stereotactic radiosurgery, and histone deacetylase inhibitors.

AB - Pineoblastomas (PBs) represent the most aggressive of the pineal parenchymal tumors. Routine treatment consists of operative management of obstructive hydrocephalus and cerebrospinal fluid studies followed by maximal resection and adjuvant chemotherapy/radiotherapy, resulting in a median survival of 20 months. Important prognostic factors for survival of patients with PB include extent of resection, age at presentation, disseminated disease, and craniospinal radiotherapy. Novel strategies being evaluated for the treatment of PB include high-dose chemotherapy with autologous stem cell therapy, stereotactic radiosurgery, and histone deacetylase inhibitors.

KW - Pineoblastoma

KW - Survival

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=79960707095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960707095&partnerID=8YFLogxK

U2 - 10.1016/j.nec.2011.05.001

DO - 10.1016/j.nec.2011.05.001

M3 - Review article

C2 - 21801990

AN - SCOPUS:79960707095

SN - 1042-3680

VL - 22

SP - 409

EP - 412

JO - Neurosurgery Clinics of North America

JF - Neurosurgery Clinics of North America

IS - 3

ER -

Contemporary Management of Pineoblastoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this